Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antibodies and immunomodulation].

F Berthoux1

  • 1Hôpital Nord, Saint-Etienne.

Presse Medicale (Paris, France : 1983)
|October 2, 2001
PubMed
Summary
This summary is machine-generated.

New protocols for anti-CD25 antibodies like daclizumab and basiliximab offer improved dosing and potential cost savings for immunosuppression. Efalizumab shows promise in specific transplant scenarios, though tolerance is a concern.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Prognostic factors in malignant hypertension selected by multivariate analysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2013
Same author

Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors.

Transplantation proceedings·2009
Same author

Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance.

Transplantation proceedings·2009
Same author

Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases.

Transplantation proceedings·2009
Same author

A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.

Clinical nephrology·2008
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Evaluating immunosuppressor induction efficacy is crucial, comparing anti-CD25 antibodies (daclizumab, basiliximab) with established agents (anti-lymphocyte globulins, anti-OKT3).
  • Existing effective immunosuppressants have significant side effects, necessitating exploration of safer alternatives.
  • Interleukin-2 receptor (IL-2R) blockade is a key strategy in immunosuppression.

Purpose of the Study:

  • To compare the efficacy and administration protocols of anti-CD25 antibodies, daclizumab and basiliximab, with other immunosuppressive agents.
  • To assess the potential of newer compounds like efalizumab in specific transplantation contexts.
  • To evaluate alternative dosing regimens for improved patient compliance and cost-effectiveness.

Main Methods:

Related Experiment Videos

  • Review of recent studies on daclizumab, basiliximab, and efalizumab.
  • Analysis of dosing protocols, receptor blockade duration, and reported efficacy.
  • Comparison of novel agents with traditional immunosuppressants like anti-lymphocyte globulins and anti-OKT3.

Main Results:

  • Daclizumab: A simplified 2-injection protocol (1 mg/kg) blocks IL-2R for over 10 weeks in 98% of recipients, offering ease of use and cost reduction.
  • Basiliximab: Administered as 2 doses (20 mg) on days 0 and 4, or a single 40 mg dose on day 1, shows comparable efficacy.
  • Efalizumab: While showing poor tolerance and efficacy as a standalone treatment, it demonstrates effectiveness in combination with plasmapheresis and IVIg for positive crossmatch or acute rejection cases.

Conclusions:

  • Simplified dosing regimens for daclizumab and basiliximab enhance practicality and potentially reduce costs in immunosuppressive therapy.
  • Efalizumab, despite limitations, holds potential in specific high-risk transplantation scenarios when used adjunctively.
  • Further research is needed to fully establish the long-term efficacy and safety profiles of these novel immunosuppressive strategies.